Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eurand has said that the FDA accepted and has granted priority review for Zentase new drug application.
Subscribe to our email newsletter
Zentase is a porcine-derived pancreatic enzyme replacement therapy which is being developed to treat pancreatic insufficiency.
Gearoid Faherty, CEO of Eurand, said: “We understand that the typical FDA review period of a drug with priority review status is six months versus a standard 10-month review. In the interim, we remain focused on the build-out of our US specialty sales force in preparation for the potential commercialization of Zentase.”